Abzena applies precision chemistry to develop protein and peptide-based drugs. The company has three proprietary precision chemistry technologies for attaching one or more molecules of the polymer poly (ethylene glycol) (PEG) to any therapeutic peptide or protein to slow its elimination from the body. This allows patients to have fewer injections and can create more efficacious drugs. The company also offers a suite of services and technologies to enable the development of better biopharmaceuticals. These include immunogenicity assessment, antibody drug conjugates, antibody/protein engineering, optimisation of pharmacokinetics and cell line development.